Research Capital Corporation analyst André Uddin is staying bullish on biotech name IMV (IMV Stock... Read More
2020 has certainly been one for the ages and from an investment point of view the healthcare sector ... Read More
Impressive cancer trial results are keeping Industrial Alliance Securities analyst Chelsea Stellick ... Read More
Echelon Capital Markets analyst Douglas Loe is staying bullish on Canadian clinical-stage biopharmac... Read More
Biopharm company IMV (IMV Stock Quote, Chart, News TSX:IMV) is a high risk, high reward stock you sh... Read More
Should you be buying IMV (IMV Stock Quote, Chart, News TSX:IMV)? The Halifax-based biopharm company ... Read More
Echelon Wealth Partners analyst Douglas Loe said there’s no change to his investment thesis on cli... Read More
There’s no change in analyst Douglas Loe’s valuation or development timelines for clinical-stage... Read More
New clinical results from biopharm company IMV (IMV Stock Quote, Chart, News TSX:IMV) signal a less ... Read More
Immuno-oncology company IMV (IMV Stock Quote, Chart TSX:IMV) has announced new data from its lead ca... Read More
Echelon Wealth Partners analyst Doug Loe is holding steady on his estimation of IMV (IMV Stock Quote... Read More
Biotech company IMV (IMV Stock Quote, Chart TSX:IMV) got a target reduction Friday from Mackie Resea... Read More
On its own, the potential of IMV Inc.’s (IMV Stock Quote, Chart TSX:IMV) cancer-fighting drug DPX-... Read More
Biotech company IMV (Quote, Chart TSX:IMV) has reported positive preliminary results from its trial ... Read More
A new development at IMV (Quote, Chart TSX:IMV) has Mackie Research Capital analyst André Uddin mai... Read More
Immune therapy vaccine developer IMV (TSX, NASDAQ:IMV) just released its second quarter financials, ... Read More
Douglas Loe of Echelon Wealth Partners feels that data from immune therapy developer IMV’s (TSX, N... Read More
While still in the early stages of clinical testing of its cancer vaccine DPX-Survivac, IMV Inc.’s... Read More
Share
